Chemoprevention of breast cancer

Southern Medical Journal

Volumn 94, Issue 1, 2001, Pages 7-15

  Dalton, Rory R ^a   Kallab, Andre M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; DRUG CONTRAINDICATION; ENDOMETRIUM TUMOR; EUROPE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; METHODOLOGY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; EUROPE; FEMALE; HUMANS; INCIDENCE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0035234353     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200101000-00002     Document Type: Article

References (31)

1. Landis S, Murray T, Bolden S: Cancer statistics, 1998. CA Cancer J Clin 1998; 48:6-29
2. Chu KC, Tarone RE, Kessler LG, et al: Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996; 88:1571-1579
3. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988; 48:246-253
4. Key TJ, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24:29-43
5. Vogel VG: Assessing women's potential risk of developing breast cancer. Oncology (Huntingt) 1996; 10:1451-1458, 1461
6. Love RR, Vogel VG: Breast cancer prevention strategies. Oncology (Huntingt) 1997; 11:161-168
7. Cauley JA, Lucas FL, Kuller LH, et al: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer, study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130:270-277
8. Hankinson SE, Willett WC, Manson JE, et al: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90:1292-1299
9. Steinberg KK, Thacker SB, Smith J, et al: A meta-analysis of the effect of hormone replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985-1990
10. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146-151
11. London SJ, Connolly JL, Schnitt SJ, et al: A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267:941-944
12. Bodian CA, Perzin KH, Lattes R: Lobular neoplasia: long term risk of breast cancer in relation to other factors. Cancer 1996; 78:1024-1034
13. Sellers TA, Kushi LH, Potter JD, et al: Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 1992; 326:1323-1329
14. Colditz GA, Rosner BA, Speizer FE: Risk factors for breast cancer according to family history of breast cancer. Nurses' Health Study Research Group. J Natl Cancer Inst 1996; 88:365-371
15. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 1990; 82:18-21
16. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998; 339:974-984
17. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618
18. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial, report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 2:171-175
19. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. Br J Cancer 1988; 57:604-607
20. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1:117-120
21. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479-484
22. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-1467
23. Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753-758
24. Horwitz KB, Jackson TA, Bain DL, et al: Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10:1167-1177
25. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852-856
26. Davidson NE: Tamoxifen - panacea or Pandora's box? N Engl J Med 1992; 326:885-886
27. Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860-864
28. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997; 89:776-782
29. Jordan VC: Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997; 89:747-749
30. Nayfield SG, Gorin MB: Tamoxifen-associated eye disease, a review. J Clin Oncol 1996; 14:1018-1026
31. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286-294